Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in SpainReportar como inadecuado




Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Clinical and Translational Oncology

pp 1–8

First Online: 02 June 2017Received: 25 November 2016Accepted: 19 May 2017DOI: 10.1007-s12094-017-1684-4

Cite this article as: Lopez-Vivanco, G., Salvador, J., Diez, R. et al. Clin Transl Oncol 2017. doi:10.1007-s12094-017-1684-4

Abstract

PurposeTo describe healthcare professional HCP and patient time and related costs associated with trastuzumab intravenous infusion IV and trastuzumab subcutaneous SC formulations in patients with HER2-positive early breast cancer.

MethodsThis prospective, observational time, and motion study in three Spanish centers was run as a substudy of the PrefHer trial. We recorded active HCP time for trastuzumab SC and IV-related tasks and calculated HCP time as the mean sum of task times over 154 administrations 80 IV, 74 SC. We calculated mean patient infusion chair time and treatment room time. Staff costs were calculated using fully loaded salary costs based on Spanish salaries € 2012.

ResultsThe transition from trastuzumab IV to SC led to a 50% reduction in active HCP time 27.2 min 95% CI 21.8–32.6 vs. 13.2 min 95% CI 8.9–17.5 per cycle. Time savings resulted from avoiding IV catheter installation and removal, line flushing, and drug reconstitution. SC administration led to a fivefold reduction 78–85% in chair time and a fourfold reduction 59–81% in patient treatment room time, resulting in 24 h free-up time in the total treatment course 18 cycles. Total estimated direct costs were € 29,431.75 and € 28,452.12 for IV and SC, respectively, a saving of € 979.60 over a full treatment course.

ConclusionsTrastuzumab SC provided substantial time savings for HCP and patients, and reduced staff costs vs. trastuzumab IV. Reducing the use of hospital facilities may result in further savings and improved quality of medical care.

KeywordsTrastuzumab Time and motion Spain Electronic supplementary materialThe online version of this article doi:10.1007-s12094-017-1684-4 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: G. Lopez-Vivanco - J. Salvador - R. Diez - D. López - M. De Salas-Cansado - B. Navarro - J. De la Haba-Rodríguez

Fuente: https://link.springer.com/







Documentos relacionados